Raphael Pharmaceutical (RAPH) Total Current Liabilities (2020 - 2025)

Raphael Pharmaceutical (RAPH) has 6 years of Total Current Liabilities data on file, last reported at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 93.24% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 93.24% YoY), and the FY2025 full-year result was $1.5 million, up 93.24% from the prior year.
• Total Current Liabilities improved to $1.5 million in Q4 2025, from $1.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.5 million in Q4 2025 to a low of $77000.0 in Q1 2022.
• A 5-year average of $498166.7 and a median of $356000.0 in 2021 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 41.85% in 2023 and soared 482.58% in 2024, its largest moves.
• Tracing RAPH's Total Current Liabilities over 5 years: stood at $294000.0 in 2021, then slipped by 22.79% to $227000.0 in 2022, then sank by 41.85% to $132000.0 in 2023, then soared by 482.58% to $769000.0 in 2024, then soared by 93.24% to $1.5 million in 2025.
• Business Quant data shows RAPH's Total Current Liabilities at $1.5 million in Q4 2025, $1.3 million in Q3 2025, and $1.1 million in Q2 2025.